NasdaqGS:MRNABiotechs
Moderna (MRNA) Stock Looks Pricey After A 126% Return Yet Sales Stay Strong
Moderna stock has delivered a strong 126.0% return over the past year, yet the company still screens as expensive on broad valuation checks, so investors are weighing a sharp share price recovery against signals that the stock is not a clear bargain.
Over the last 1 year, Moderna has returned 126.0%, which puts recent share price momentum front and center for anyone assessing whether current levels are stretched.
The recently announced Phase 1 trial of the mRNA-1469 vaccine for Bundibugyo...